NCT02287428 2026-03-12
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
18 trialsNCT03223103 2025-09-10
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Albert Einstein College of Medicine
Phase 1 Active not recruiting
NCT04201873 2025-08-22
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT02924038 2024-06-14
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
Phase 1 Terminated
NCT01188096 2023-06-12
Poly-ICLC
Wake Forest University Health Sciences
Phase 2 Completed
NCT05557240 2022-10-12
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
Shanghai 10th People's Hospital
Phase NA Unknown
NCT03422094 2021-10-27
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00795457 2019-08-30
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT00058123 2018-08-21
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02149225 2018-08-07
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
Phase 1 Completed
NCT00052715 2018-07-18
Poly-ICLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02332889 2018-05-04
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
University of Louisville
Phase 1/2 Terminated
NCT02510950 2017-11-17
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT01241162 2017-05-09
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
University of Louisville
Phase 1 Completed
NCT01920191 2016-04-20
Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
University Hospital, Geneva
Phase 1/2 Completed
NCT00874861 2015-12-08
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
University of Pittsburgh
Phase EARLY_PHASE1 Completed